Basics Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases. IPO Date: July 12, 2012 Sector: Healthcare Industry: Biotech Market Cap: $3.77B Activated in VL: True Average Daily Range Avg Daily Range: $1.57 | 2.41% Avg Daily Range (30 D): $1.64 | 3.26% Avg Daily Range (90 D): $1.98 | 2.80% Institutional Daily Volume Avg Daily Volume: 1.56M Avg Daily Volume (30 D): 4.08M Avg Daily Volume (90 D): 2.43M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 81 Avg Trade Size (Sh.) (90 D): 71 Institutional Trades Total Inst.Trades: 13,095 Avg Inst. Trade: $4.09M Avg Inst. Trade (30 D): $3.44M Avg Inst. Trade (90 D): $4.51M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $8.66M Avg Closing Trade (30 D): $14.8M Avg Closing Trade (90 D): $15.34M Avg Closing Volume: 96.33K         News May 13, 2025 @ 9:37 PM Ten-Year Data From Roche's Breast Cancer Trial Sho... Source: Vandana Singh May 13, 2025 @ 8:14 AM 2 Stocks Near Their 52-Week Lows That Still Aren't... Source: Prosper Junior Bakiny May 5, 2025 @ 5:56 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 5, 2025 @ 5:53 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A Apr 3, 2025 @ 7:23 PM Sarepta/Roche Suspend Elevidys Gene Therapy Trials... Source: Vandana Singh Financials   TTM Q4 2024 FY 2024 Basic EPS $-4.6 $1.67 $2.47 Diluted EPS $-4.6 $1.56 $2.34 Revenue $ 744.86M $ 658.41M $ 1.9B Gross Profit $ $ $ Net Income / Loss $ -447.51M $ 159.05M $ 235.24M Operating Income / Loss $ -300.39M $ 161.68M $ 218.08M Cost of Revenue $ $ $ Net Cash Flow $ -862.14M $ 905.16M $ 674.58M PE Ratio     Splits Jul 12, 2012:   1:6